Cas:5285-60-9 4,4′-methylenebis[N-sec-butylaniline] manufacturer & supplier

Chemical Name:4,4′-methylenebis[N-sec-butylaniline]

CAS.NO:5285-60-9

Synonyms:ACETOSTAB 225;N,N’-di-sec-butyl-4,4′-methylenedianiline;POLYLINK 4200;4,4′-methylenebis(N-(sec-butyl)aniline)

Molecular Formula:C₂₁H₃₀N₂

Molecular Weight:310.47600

HS Code:2921590090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:458.2ºC at 760mmHg

Density:1.009g/cm3

Index of Refraction:1.581

PSA:24.06000

Exact Mass:310.24100

LogP:5.84420

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ACETOSTAB 225 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,4′-methylenebis(N-(sec-butyl)aniline) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ACETOSTAB 225 Use and application,ACETOSTAB 225 technical grade,usp/ep/jp grade.

Related News: As far as chemical raw materials are concerned, China occupies a large share in the field of bulk raw materials and has become one of the world’s largest suppliers of chemical raw materials. 4,4′-methylenebis[N-sec-butylaniline] manufacturer The European Medicines Agency did not say how many shots were affected, but Reuters has reported it involves millions of doses, making it harder for J&J to meet a target of delivering 55 million to Europe by end of June. 4,4′-methylenebis[N-sec-butylaniline] supplier API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. 4,4′-methylenebis[N-sec-butylaniline] vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 4,4′-methylenebis[N-sec-butylaniline] factory The European Medicines Agency did not say how many shots were affected, but Reuters has reported it involves millions of doses, making it harder for J&J to meet a target of delivering 55 million to Europe by end of June.